STOCK TITAN

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Allogene Therapeutics (ALLO), a clinical-stage biotech company focused on allogeneic CAR T products, will release its Q3 2024 financial results on November 7, 2024, after market close. The company will host a conference call and webcast at 2:00 p.m. PT/5:00 p.m. ET on the same day. Interested parties can access the webcast through the company's website, with a replay available for approximately 30 days. Those wishing to ask questions during the call must register to receive a personal PIN for access.

Allogene Therapeutics (ALLO), una compagnia biotech in fase clinica focalizzata su prodotti CAR T allogenici, pubblicherà i suoi risultati finanziari del Q3 2024 il 7 novembre 2024, dopo la chiusura del mercato. L'azienda organizzerà una teleconferenza e un webcast alle 14:00 PT/17:00 ET nello stesso giorno. Le parti interessate possono accedere al webcast attraverso il sito web dell'azienda, con una registrazione disponibile per circa 30 giorni. Coloro che desiderano porre domande durante la chiamata devono registrarsi per ricevere un PIN personale per l'accesso.

Allogene Therapeutics (ALLO), una empresa biotecnológica en etapa clínica centrada en productos CAR T alogénicos, publicará sus resultados financieros del tercer trimestre de 2024 el 7 de noviembre de 2024, después del cierre del mercado. La empresa realizará una llamada de conferencia y un webcast a las 2:00 p.m. PT/5:00 p.m. ET en el mismo día. Las partes interesadas pueden acceder al webcast a través del sitio web de la empresa, con una repetición disponible durante aproximadamente 30 días. Aquellos que deseen hacer preguntas durante la llamada deben registrarse para recibir un PIN personal para acceder.

Allogene Therapeutics (ALLO), 동종 CAR T 제품에 주력하는 임상 단계 생명공학 회사는 2024년 3분기 재무 결과2024년 11월 7일 시장 마감 후 발표할 예정입니다. 회사는 같은 날 오후 2시 PT/오후 5시 ET에 컨퍼런스 콜 및 웹캐스트를 개최할 것입니다. 관심 있는 사람들은 회사 웹사이트를 통해 웹캐스트에 접근할 수 있으며, 약 30일 동안 재생이 가능합니다. 통화 중 질문을 하고 싶은 분은 개인 PIN을 수신하기 위해 등록해야 합니다.

Allogene Therapeutics (ALLO), une entreprise biopharmaceutique en phase clinique axée sur les produits CAR T allogéniques, publiera ses résultats financiers pour le T3 2024 le 7 novembre 2024, après la clôture du marché. L'entreprise organisera une téléconférence et un webinaire le même jour à 14h00 PT/17h00 ET. Les parties intéressées peuvent accéder au webinaire via le site web de l'entreprise, avec un replay disponible pendant environ 30 jours. Ceux qui souhaitent poser des questions pendant l'appel doivent s'inscrire pour recevoir un code PIN personnel pour y accéder.

Allogene Therapeutics (ALLO), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf allogene CAR-T-Produkte spezialisiert hat, wird seine Finanzergebnisse für das 3. Quartal 2024 am 7. November 2024, nach Börsenschluss, veröffentlichen. Das Unternehmen wird am selben Tag um 14:00 Uhr PT/17:00 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten. Interessierte Parteien können über die Website des Unternehmens auf den Webcast zugreifen, der für etwa 30 Tage verfügbar ist. Personen, die während des Anrufs Fragen stellen möchten, müssen sich registrieren, um eine persönliche PIN für den Zugang zu erhalten.

Positive
  • None.
Negative
  • None.
  • Conference Call and Webcast Scheduled for November 7, 2024 at 2:00 p.m. PT/5:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update on November 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET.

Listen-Only Webcast
The listen-only webcast will be made available on the Company's website at www.allogene.com under the Investors tab in the News and Events section. A replay will be available on the Company's website for approximately 30 days.

Conference Call Registration
If you would like the option to ask a question on the conference call, please use this link to register. Upon registering for the conference call, you will receive a personal PIN to access the call.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow Allogene Therapeutics on X and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things Allogene’s ability to develop and deliver readily available allogeneic CAR T products for the treatment of cancer and autoimmune disease on-demand, more reliably, and at greater scale to more patients. Various factors may cause material differences between Allogene’s expectations and actual results, including risks and uncertainties related to our product candidates being based on novel technologies, which makes it difficult to predict the time and cost of product candidate development, the safety or efficacy of a product candidate, and whether a product candidate will receive regulatory approval, which could prevent or delay commercialization. These and other risks are discussed in greater detail in Allogene’s filings with the SEC, including without limitation under the “Risk Factor” heading in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
EVP, Chief Corporate Affairs & Brand Strategy Officer
Christine.Cassiano@allogene.com


FAQ

When will Allogene Therapeutics (ALLO) report Q3 2024 earnings?

Allogene Therapeutics will report Q3 2024 financial results on November 7, 2024, after market close.

What time is Allogene Therapeutics (ALLO) Q3 2024 earnings call?

The earnings call is scheduled for November 7, 2024, at 2:00 p.m. PT/5:00 p.m. ET.

How can I access Allogene Therapeutics (ALLO) Q3 2024 earnings call?

You can access the webcast through www.allogene.com under the Investors tab. To ask questions during the call, you must register to receive a personal PIN.

Allogene Therapeutics, Inc.

NASDAQ:ALLO

ALLO Rankings

ALLO Latest News

ALLO Stock Data

602.24M
209.11M
17.48%
83.78%
18.8%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SOUTH SAN FRANCISCO